Abstract Abstract Abstract Abstract AIM: To determine common NOD2/CARD15 mutations and TLR4 D299G polymorphism in Hungarian patients with CD.
INTRODUCTION INTRODUCTION INTRODUCTION INTRODUCTION INTRODUCTION
Inflammatory bowel disease (IBD) is a multifactorial polygenic disease with probable genetic heterogeneity. In addition to genetic predisposition, various environmental and host factors (e.g. genetic, epithelial, immune and nonimmune factors) play a major role in the pathogenesis of IBD. Crohn's disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract. Extensive heterogeneity is observed in terms of disease presentation, behavior, and response to treatment [1, 2 ] . Attempts have been made to define clinical subgroups on the basis of age at onset, disease location, extent (diffuse or localized) and behavior (primary inflammatory, fistulating, or fibrostenotic). CD has a strong genetic component, with a lifetime risk of 10-20% to develop IBD in the presence of an affected first-degree relative [1] . The concordance rate of affected siblings for age at onset, disease site, behavior and presence of extra-intestinal manifestation is as high as 80%. Since the first report of Hugot et al. [3] in 1996, seven IBD loci have been identified on chromosomes 16q12 (IBD1), 12q13 (IBD2), 6p13 (IBD3), 14q11 (IBD4), 5q31-33 (IBD5), 19p13 (IBD6) and 1p (IBD7) [4] [5] [6] . These seven loci are convincingly replicated. Some genetic markers increase the risk of ulcerative colitis or CD while others are associated with a particular phenotypic expression like disease location and/or behavior. The NOD2/CARD15 gene is located in the IBD1 region. NOD2/CARD15 is a cytoplasmatic protein expressed in peripheral blood monocytes, Paneth cells and intestinal epithelial cells and is related structurally to the welldescribed R proteins in plants, which mediate host resistance to microbial pathogens [7] and induce the NF-κB pathway [8] . Variant alleles result in reduced NF-κB activity [9] . Variant NOD2/CARD15 alleles are also associated with reduced α-defensin release from Paneth cells in response to bacteria [10] . Of particular importance is the C-terminus leucine-rich repeat domain, reportedly the major structural motif that functions as a pattern-recognition receptor for broad types of microbial components, such as bacterial lipopolysaccharides (LPS) and peptidoglycan (including MDP) [11] . Two single nucleotide polymorphisms of NOD2/ CARD15 (SNP8: Arg702Trp and SNP12: Gly908Arg) and a frame shift mutation (SNP13: Leu1007insC) have been shown by three independent groups to be associated with susceptibility to CD [12] [13] [14] . The presence of one variant allele increases the risk for developing CD 1.5-4.3-fold, and the presence of two copies up to 20-40-fold [13] [14] [15] . It has also been suggested that the presence of variant alleles is associated with ileal disease and fibrostenosing or fistulizing behavior in some [15, 16] , but not in all the studies [17, 18] . However, there are significant geographical differences in the frequency of these alleles. They are not found in Japan and China [19, 20] and are less frequent in Finland [21] than in Western Europe. There are only limited data in patients from Central-Eastern European countries like Hungary. [22] . Recently it has been suggested that the interaction of LPS with TLR4/MD2 contributes to the perpetuation of the inflammatory epithelial cell injury via TNFα-induced alterations of enterocyte turnover in an autoparacrine/ paracrine manner [23] . TLRs may also influence the nature of the immune response, in particular by skewing T cells toward a Th1 or Th2 profile. Myeloid cells are exquisitely sensitive to TLR ligands and produce significant IL-12p40 and appear to play key roles in the initiation and possibly the Th1/Th2 skewing of inflammatory responses. In this model the inflammation would normally be controlled by myeloid or lymphocyte-derived IL-10 acting through Stat3 in myeloid cells to block further production of IL-12/IL-23 and skewing to Th1 response [24] . TLR4 is upregulated in the intestinal epithelial cells in patients with CD. In contrast, the expressions of TLR2 and TLR5 are unchanged, while TLR3 is down-regulated [25] . The D299G (Asp299Gly) polymorphism of TLR4 gene is associated with LPS hyporesponsiveness [26] and recently an association between TLR4 mutation and CD was reported in one study [27] , but not in another [28] . In view of the limited data on the prevalence of NOD2/CARD15 mutations in Eastern European countries, our aim was to investigate the presence of the common three and other exon4 variants of NOD2/CARD15 as well as the presence of functional D299G polymorphism of the TLR4 gene in three large cohorts of Hungarian patients with CD. We also aimed to investigate the possible association between genotype and clinical characteristics of the disease. . CD patients, with a follow-up time of at least one year were included. The diagnosis was based on the Lennard-Jones criteria [29] . The clinical characteristics of the patients are summarized in Table 1 . The disease phenotype (age at onset, duration, location and behavior) was determined according to the Vienna classification [30] . Perianal involvement, presence of extraintestinal manifestations (EIM; arthritis: peripheral and axial; ocular manifestations: conjunctivitis, uveitis, iridocyclitis; skin lesions: erythema nodosum, pyoderma gangrenosum; hepatic manifestations: primary sclerosing cholangitis [PSC]), frequency of flare-ups (frequent flare-up: >1/year), therapeutic effectiveness (e.g. steroid and/or immunosuppressive resistance), need for surgery (resections). Presence of familial IBD and smoking habits were investigated by filling in a questionnaire.
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The control group for mutation analysis consisted of 200 age-and gender-matched healthy subjects [male/female: 102/98, age: 38.05 (SD 10.7) years]. The study was approved by the Semmelweis University Regional and Institutional Committee of Science and Research Ethics (81/2003). Each patient was informed of the nature of the study and signed the informed consent form.
Detection of NOD2/CARD15 SNP8, 12, 13 and exon4 mutations
Genomic DNA was isolated from whole blood according to the QIAamp DNA blood mini kit (QIAGEN GmbH, Germany). Each exon was amplified by PCR using previously published primer sequences [17] . The initial denaturation step (at 94 for 7 min) was to activate AmpliTaq Gold (Applied Biosystems, Foster City, CA, USA), followed by 33 cycles (at 94 for 20 s, at 61 for 30 s, at 72 for 25 s) with a final extension step at 72 for 7 min. Then denaturing high-performance liquid chromatography (dHPLC, wave DNA fragment analysis system, Transgenomic Limited, UK) were performed to analyze the exons. PCR products were denatured as a last step at 94 for 5 min to induce heteroduplex formation during the following 30 min of slowly cooling down to room temperature. Five microliters of these PCR products were then automatically loaded onto the DNASep cartridge (Transgenomic Limited, UK) in the wave system. The specific acetonitrile gradient to elute each exon was established by using the WaveMaker 3.4.4 software. The particular run temperature for the detection of each SNP was determined using positive controls, which were kindly provided by Dirk Seegert from Kiel, Germany.
Finally, when a sequence variation was observed in the dHPLC profile, the relevant PCR product was sequenced on both strands to confirm the alteration. Sequencing reactions were performed with the ABI BigDye terminator cycle sequencing kit v1.1 (Applied Biosystems) and samples were sequenced on an ABI Prism 310 genetic analyzer (Applied Biosystems).
Detection of TLR4 D299G polymorphism
The TLR4 D299G polymorphism was detected by PCR-RFLP (PTC-200 thermocycler, MJ Research Inc., MA, USA) using previously published primers and conditions [31] . For the overnight digestion of the amplified DNA, NcoI enzyme (New England Biolabs, London, UK) was used and the fragments were separated and visualized by gel electrophoresis (3% NuSieve® GTG agarose gel BMA, Rockland, ME, USA). (Tables 3 and 5) . More homozygous (60%) or compound heterozygous (69.2%) patients tended to be females compared to heterozygous (46.6%) patients and non-carriers (49.1%). The use of immunosuppressive drugs (P = 0.04) and the need for surgery (resection, P = 0.006) were more frequent in carriers of the mutation ( Table 6 ). The percentage of patients with resection was even higher in compound heterozygous patients (65.4%, 17/26, P = 0.006 compared to non-carriers by Fischer exact test). The presence of variant NOD2/CARD15 allele affected disease phenotype and was associated with earlier disease onset (26.4 vs 29.8 years, P = 0.0006), the site of involvement (ileal involvement: 81.6% vs non-carriers: 69.0%, OR = 1.99, 95%CI: 1.29-3.08, P = 0.02) and with stricturing behavior (OR = 1.69, 95%CI: 1.13-2.55, P = 0.02, Tables 6, 7 ). The presence of NOD2/ CARD15 variant alleles was not associated with the presence of perianal manifestation associated disease duration, more frequent relapses, familial disease and presence of EIMs or smoking habits. EIMs were tendentiously even less frequent in patients carrying two mutant alleles. The TLR4 D299G mutation was not different between patients and controls (9.9% vs 12.0%, P = NS). The frequency of familial IBD tended to be lower in patients with TLR4 mutation (5.7% vs without 12.6%, P = NS). However, the presence of variant TLR4 allele strengthened genotype-phenotype associations (Figure 1 In a logistic regression model, exploring the effect of NOD2, TLR4 carriage, age at presentation, location, behavior and smoking, presence of NOD2 mutation (coefficient = 0.54, OR = 1.71, 95%CI: 1.13-2.62, P = 0.01) and noninflammatory behavior (coefficient = 1.26, OR = 3.53, 95%CI: 2.76-4.51, P = 0.001) but not location, smoking or carriage of TLR4 variant allele were independently associated with the need for surgery. However, the percentage of multiple resections was not different between carriers and non-carriers (13.0% vs 11.1%, P = NS).
Statistical analysis
DISCUSSION DISCUSSION DISCUSSION DISCUSSION DISCUSSION
This is the first report on the prevalence of NOD2/ CARD15 mutations and TLR4 D299G polymorphism in patients with CD from a Central Eastern European country. The reported rates of 35.1% of patients carrying NOD2/ CARD15 mutations in CD and 16.5% in controls are in concordance with previously reported rates of 30-50% in CD and 7-20% in controls from other European regions [12, [15] [16] [17] [32] [33] [34] [35] . Only in Finland (which by language is related to Hungary), the rate of NOD2 mutations was considerably lower (8.7% vs 3.5% in controls) [21] . Similar low frequencies were found in other Northern European countries (8% in Denmark, and 8.9% in patients from Norway) [28] . The prevalence of SNP8, 12 and 13 was 3.3, 0.6 and 4.8% in the Finish study (in controls it was 1.8%, 0 and 1.7%) with only the SNP13 being more common in CD compared to controls. In our study, the rates were 11.6, 6.3 and 19.4%, which are in concordance with other studies from Europe (6.7-12.5%, 3.3-6.1% and 6.6-16% in CD and 3.5-6.9%, 0.6-3.0% and 1.0-4.4% in controls) [17, 33] . The phenotype-genotype correlations in our cohort were also similar to those reported in various European countries [6, 17, 36] . Ileal involvement in Hungarian patients was more frequent in NOD2 mutation carriers (81.6%), while disease confined to the colon alone was less frequent (17.8%), especially in patients with two alleles, in the presence of SNP13 or TLR4 variant allele. Like in other countries, in our study, carriage of variant NOD2/CARD15 allele was associated with stricturing disease (30.8% vs 20.8%), while variant alleles were less frequent in patients with inflammatory disease. More patients with stricturing disease carried a mutant NOD2/CARD15 allele (44.5%) than patients without strictures (32.1%, P<0.01). Steroid use and efficacy were similar in mutation carriers and non-carriers, but a higher percentage of patients carrying NOD2/CARD15 variant allele needed azathioprine during the course of the disease, especially in the presence of two risk alleles. There are conflicting data on the association of NOD2/CARD15 mutations and need for surgery in CD patients: association [37] and also lack of association [16, 17] have been reported. In a French follow-up study [18] , ileal location was associated with early development of stricturing disease while a high number of flares was associated with a penetrating pattern, but this was not affected by the presence of variant NOD2/CARD15 allele. Active smoking was also associated with early development of penetrating disease. In our study there was no difference in the proportion of smokers between carriers and non-carriers of NOD2/CARD15 variant allele.
The importance of TLR4 D299G polymorphism in CD is less clear. In contrast to Franchimont et al. [27] who reported a two-fold elevation in allele frequency of TLR4 D299G (11% vs 5%, OR = 2.31), we found no difference in the prevalence of TLR4 D299G polymorphism in CD patients and controls, suggesting that this polymorphism is not essential in the development of the disease. There is also no difference in TLR4 allele frequency between IBD patients and controls in concordance with the preliminary results of the EC-IBD study group [28] . However, the rate of variant allele is higher in the Hungarian controls compared to the study of Franchimont et al. [27] . We also found a tendency of decreased frequency of the TLR4 D299G variant allele in patients with familial disease (6% vs sporadic 13%, P = NS).
In our study, no clear-cut phenotype-genotype associations were observed in TLR4 D299G carriers. The presence of variant TLR4 allele tendencially associated with early disease onset (P = 0.06), along with a gene-dosage effect. The earliest onset (23 years) was observed in carriers of both variant NOD2/CARD15 and TLR4 alleles (vs noncarriers 30.2 years, P = 0.01). The presence of TLR4 variant allele did not affect disease behavior (in patients with variant TLR4 allele, stricturing disease was present in 33.3% of NOD2 carriers vs 17.1% of NOD2/CARD15 non-carriers).
In summary, this is the first report on the prevalence of NOD2/CARD15 mutations and TLR4 D299G polymorphism in patients with CD from a Central Eastern European country. It confirms that the risk for CD is increased in carriers of R702W, R703C and 3020insC mutations, while the presence of G908R or TLR4 D299G polymorphism is not different from the controls. The presence of variant NOD2/CARD15 alleles is associated with early disease onset, ileal disease and stricturing disease behavior and increases need for surgery, while the presence of TLR4 D299G variant allele exhibits a disease modifier effect.
